Predictive Oncology developed predictive models from 21 compounds from NPDC

Predictive Oncology (POAI) announced that it has successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core, NPDC, at the University of Michigan Life Sciences Institute. Predictive Oncology, in partnership with the NPDC, recently evaluated 21 novel compounds using Predictive’s active machine learning platform. The platform is used to shorten the time necessary to select drug candidates, while increasing the probability of technical success using live-cell tumor samples from its extensive biobank of frozen specimens. “Three compounds consistently demonstrated strong tumor drug response across all tumor types tested and demonstrated a stronger response than Doxorubicin, a benchmark compound, across tumor types,” said Dr. Arlette Uihlein, SVP of Translational Medicine and Drug Discovery at Predictive Oncology. “A fourth drug showed a strong response in the ovary and colon models and three additional compounds demonstrated the most ‘hit responses’ across all three tumor types.”